Amicus Therapeutics (NASDAQ: FOLD) director equity paid out at $14.50 in BioMarin deal

Rhea-AI Filing Summary

AMICUS THERAPEUTICS, INC. director Eiry Roberts reported disposing of equity in connection with the consummation of the company’s acquisition by BioMarin Pharmaceutical Inc.

The filing shows a disposition of 76,275 shares of Common Stock at $14.50 per share, tied to the merger consideration. Footnotes state this amount included 55,861 shares of Common Stock and 20,414 restricted stock units, with the restricted stock units vesting in full at closing of the merger.

Multiple fully vested stock option grants were also disposed of to the issuer and converted into a cash right. These covered 74,872, 42,467, 30,474, 45,423 and 40,625 underlying shares at exercise prices ranging from $5.96 to $12.62 per share. For each option, the holder became entitled to a cash payment equal to the excess of $14.50 per share over the applicable exercise price, multiplied by the number of shares subject to that option. Following these transactions, the reporting person shows 0 shares and 0 options held in this filing.

Insights

Equity compensation analyst

Director’s stock and options were cashed out at the $14.50 merger price.

The Form 4 shows Eiry Roberts, a director of Amicus Therapeutics, surrendering common shares, restricted stock units, and stock options as part of the completed acquisition by BioMarin Pharmaceutical Inc. This reflects standard equity treatment on a change of control.

Common shares and fully vested restricted stock units were effectively valued at $14.50 per share, matching the merger consideration. Each vested option was canceled and replaced with a cash right equal to $14.50 minus the option’s exercise price, times the shares covered, so only in‑the‑money value was paid.

After these dispositions, the filing shows no remaining common stock or options held by the reporting person. Economically, this is a closing mechanics event rather than a discretionary trade, and it aligns the director’s equity treatment with the merger terms already agreed for shareholders.

Insider Trade Summary

6 transactions reported

Mixed 6 txns

Insider ROBERTS EIRY

Role null

Type	Security	Shares	Price	Value
Disposition	Stock Options (right to buy)	40,625	$0.00	--
Disposition	Stock Options (right to buy)	45,423	$0.00	--
Disposition	Stock Options (right to buy)	30,474	$0.00	--
Disposition	Stock Options (right to buy)	42,467	$0.00	--
Disposition	Stock Options (right to buy)	74,872	$0.00	--
Disposition	Common Stock	76,275	$14.50	$1.11M

Holdings After Transaction: Stock Options (right to buy) — 0 shares (Direct, null); Common Stock — 0 shares (Direct, null)

Footnotes (1)

1. The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 55,861 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger). In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. Each Option vested in full in connection with consummation of the Merger.

Key Figures

Common shares disposed: 76,275 shares at $14.50 Included common shares: 55,861 shares Restricted stock units vested: 20,414 RSUs +5 more

8 metrics

Common shares disposed 76,275 shares at $14.50 Common Stock disposition tied to merger consideration

Included common shares 55,861 shares Portion of 76,275 total common shares mentioned in footnote

Restricted stock units vested 20,414 RSUs RSUs that vested in full upon merger consummation

Option block 1 74,872 options at $5.96 Fully vested stock options canceled for cash

Option block 2 42,467 options at $10.27 Fully vested stock options canceled for cash

Option block 3 30,474 options at $12.62 Fully vested stock options canceled for cash

Option block 4 45,423 options at $8.55 Fully vested stock options canceled for cash

Post-transaction holdings 0 shares and 0 options Reported holdings following merger-related dispositions

Key Terms

restricted stock units, stock options ("Option"), Merger, exercise price, +1 more

5 terms

restricted stock units financial

"20,414 restricted stock units (which vested in full in connection with consummation of the Merger)"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

stock options ("Option") financial

"each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment"

Merger financial

"disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger")"

A merger is when two companies combine into a single business, with ownership and control reorganized so they operate as one entity. For investors it matters because mergers can change the value and risk of holdings—shares may be exchanged, diluted, or rise if the combined company saves costs or gains market power, and the deal often depends on regulatory approval and successful integration like two households joining resources and routines.

exercise price financial

"equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

cash payment financial

"was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROBERTS EIRY

(Last) (First) (Middle)

47 HULFISH STREET

(Street)

PRINCETON NEW JERSEY 08542

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AMICUS THERAPEUTICS, INC. [ FOLD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/27/2026		D		76,275(1)	D	$14.5	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$10.71	04/27/2026		D(2)			40,625	(3)	06/10/2031	Common Stock	40,625	(2)	0	D
Stock Options (right to buy)	$8.55	04/27/2026		D(2)			45,423	(3)	06/09/2032	Common Stock	45,423	(2)	0	D
Stock Options (right to buy)	$12.62	04/27/2026		D(2)			30,474	(3)	06/08/2033	Common Stock	30,474	(2)	0	D
Stock Options (right to buy)	$10.27	04/27/2026		D(2)			42,467	(3)	06/06/2034	Common Stock	42,467	(2)	0	D
Stock Options (right to buy)	$5.96	04/27/2026		D(2)			74,872	(4)	06/05/2035	Common Stock	74,872	(2)	0	D

Explanation of Responses:

1. The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 55,861 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger).

2. In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option.

3. Each Option was fully vested.

4. Each Option vested in full in connection with consummation of the Merger.

	/s/ Christian Formica, Attorney-in-Fact	04/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)